{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:56:13Z","timestamp":1791568573790,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institute for Health Research (NIHR) Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance","award":["NIHR200915"],"award-info":[{"award-number":["NIHR200915"]}]},{"name":"National Institute for Health Research (NIHR) Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance","award":["NIHR200915"],"award-info":[{"award-number":["NIHR200915"]}]},{"name":"National Institute for Health Research (NIHR) Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance","award":["NIHR200915"],"award-info":[{"award-number":["NIHR200915"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Serial measurements of C-reactive protein (CRP) are often taken in hospitals to assess recovery from infection, but their utility remains debated. Previous studies, including our development of CRP centile reference charts for suspected bloodstream infections (BSI), suggest variability in CRP responses across infection types. Here we investigated the association between serial CRP percentile changes, antibiotic prescribing patterns, and patient outcomes in a large cohort with suspected infection, acknowledging that CRP is one of multiple factors in clinical decision-making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analysed 51,544 suspected infection episodes (defined by blood culture collection) from 36,578 patients in Oxfordshire, UK (2016\u20132021). Episodes were categorised by blood culture results: Gram-positive, Gram-negative, polymicrobial, contaminants, or culture-negative (having previously shown that 51% culture-negatives have CRP responses indistinguishable from culture-positives). The spectrum of antibiotic prescriptions and their changes over time were tracked. Multinomial logistic regression, adjusted for clinical covariates, assessed the association between CRP percentile changes and subsequent prescribing decisions. Linear mixed models evaluated CRP trajectories post-prescribing, and logistic regression associations between early CRP changes (days 1\u20134) and 5\u201330-day mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Broad-spectrum antibiotics were predominantly used within the first three days after blood culture collection, followed by a notable shift to narrow-spectrum antibiotics for Gram-positive infections, but with slower de-escalation for Gram-negative and polymicrobial infections. CRP percentile changes were modestly associated with subsequent antibiotic adjustments; in particular, suboptimal recovery, indicated by an increase in CRP centiles, was associated with a higher rate of antibiotic escalation (16.5% vs. 10.7% in expected recovery) and, conversely, faster than expected recovery in CRP was associated with de-escalation (23.6% vs. 17.2%). However, 61.8% of decisions were unchanged despite CRP trends. The relationship between various prescribing decisions and subsequent CRP percentile changes was complex and challenging to estimate, likely due to testing bias. CRP percentile changes during the 4 days post blood culture collection were strongly associated with 5\u201330-day mortality, highlighting their potential utility as a prognostic indicator.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While CRP monitoring can inform antibiotic stewardship, its association with prescribing decisions is probably only modest, underscoring the need to integrate a range of clinical factors to optimise infection management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-025-11381-9","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T14:47:05Z","timestamp":1754405225000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Interplay between C-reactive protein responses and antibiotic prescribing in people with suspected infection"],"prefix":"10.1186","volume":"25","author":[{"given":"Qingze","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Ho","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders Skyrud","family":"Danielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augustine","family":"Luk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Eyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Sarah","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"11381_CR1","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/1469-0691.12195","volume":"19","author":"M Goto","year":"2013","unstructured":"Goto M, Al-Hasan MN. Overall burden of bloodstream infection and nosocomial bloodstream infection in North America and Europe. Clin Microbiol Infect. 2013;19:501\u20139.","journal-title":"Clin Microbiol Infect"},{"key":"11381_CR2","unstructured":"UK Health Security Agency. Start smart then focus: antimicrobial stewardship toolkit for inpatient care settings. GOV.UK. 2015. https:\/\/www.gov.uk\/government\/publications\/antimicrobial-stewardship-start-smart-then-focus\/start-smart-then-focus-antimicrobial-stewardship-toolkit-for-inpatient-care-settings. Accessed 3 Jan 2024."},{"key":"11381_CR3","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for Sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801\u201310.","journal-title":"JAMA"},{"key":"11381_CR4","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s00134-022-06956-y","volume":"49","author":"P P\u00f3voa","year":"2023","unstructured":"P\u00f3voa P, Coelho L, Dal-Pizzol F, Ferrer R, Huttner A, Conway Morris A, et al. How to use biomarkers of infection or sepsis at the bedside: guide to clinicians. Intensive Care Med. 2023;49:142\u201353.","journal-title":"Intensive Care Med"},{"key":"11381_CR5","doi-asserted-by":"publisher","first-page":"106156","DOI":"10.1016\/j.jinf.2024.106156","volume":"88","author":"Q Gu","year":"2024","unstructured":"Gu Q, Wei J, Yoon CH, Yuan K, Jones N, Brent A, et al. Distinct patterns of vital sign and inflammatory marker responses in adults with suspected bloodstream infection. J Infect. 2024;88:106156.","journal-title":"J Infect"},{"key":"11381_CR6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/s13054-021-03736-w","volume":"25","author":"MS Niederman","year":"2021","unstructured":"Niederman MS, Baron RM, Bouadma L, Calandra T, Daneman N, DeWaele J, et al. Initial antimicrobial management of sepsis. Crit Care. 2021;25:307.","journal-title":"Crit Care"},{"key":"11381_CR7","doi-asserted-by":"publisher","first-page":"4851","DOI":"10.1128\/AAC.00627-10","volume":"54","author":"M Paul","year":"2010","unstructured":"Paul M, Shani V, Muchtar E, Kariv G, Robenshtok E, Leibovici L. Systematic review and Meta-Analysis of the efficacy of appropriate empiric antibiotic therapy for Sepsis. Antimicrob Agents Chemother. 2010;54:4851\u201363.","journal-title":"Antimicrob Agents Chemother"},{"key":"11381_CR8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s00134-013-3077-7","volume":"40","author":"J Garnacho-Montero","year":"2014","unstructured":"Garnacho-Montero J, Guti\u00e9rrez-Pizarraya A, Escoresca-Ortega A, Corcia-Palomo Y, Fern\u00e1ndez-Delgado E, Herrera-Melero I, et al. De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med. 2014;40:32\u201340.","journal-title":"Intensive Care Med"},{"key":"11381_CR9","doi-asserted-by":"publisher","first-page":"R225","DOI":"10.1186\/cc9373","volume":"14","author":"J Morel","year":"2010","unstructured":"Morel J, Casoetto J, Josp\u00e9 R, Aubert G, Terrana R, Dumont A, et al. De-escalation as part of a global strategy of empiric antibiotherapy management. A retrospective study in a medico-surgical intensive care unit. Crit Care. 2010;14:R225.","journal-title":"Crit Care"},{"key":"11381_CR10","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1177\/0885066618762747","volume":"33","author":"M Campion","year":"2018","unstructured":"Campion M, Scully G. Antibiotic use in the intensive care unit: optimization and De-Escalation. J Intensive Care Med. 2018;33:647\u201355.","journal-title":"J Intensive Care Med"},{"key":"11381_CR11","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.hrtlng.2016.06.001","volume":"45","author":"Y Guo","year":"2016","unstructured":"Guo Y, Gao W, Yang H, Ma C, Sui S. De-escalation of empiric antibiotics in patients with severe sepsis or septic shock: A meta-analysis. Heart Lung. 2016;45:454\u20139.","journal-title":"Heart Lung"},{"key":"11381_CR12","doi-asserted-by":"publisher","first-page":"e022133","DOI":"10.1136\/bmjopen-2018-022133","volume":"8","author":"D Petel","year":"2018","unstructured":"Petel D, Winters N, Gore GC, Papenburg J, Beltempo M, Lacroix J, et al. Use of C-reactive protein to tailor antibiotic use: a systematic review and meta-analysis. BMJ Open. 2018;8:e022133.","journal-title":"BMJ Open"},{"key":"11381_CR13","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/cpt.2194","volume":"110","author":"LBS Aulin","year":"2021","unstructured":"Aulin LBS, de Lange DW, Saleh MAA, van der Graaf PH, V\u00f6ller S, van Hasselt JGC. Biomarker-Guided individualization of antibiotic therapy. Clin Pharmacol Ther. 2021;110:346\u201360.","journal-title":"Clin Pharmacol Ther"},{"key":"11381_CR14","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s15010-007-7077-9","volume":"36","author":"X Schmit","year":"2008","unstructured":"Schmit X, Vincent JL. The time course of blood C-reactive protein concentrations in relation to the response to initial antimicrobial therapy in patients with Sepsis. Infection. 2008;36:213\u20139.","journal-title":"Infection"},{"key":"11381_CR15","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/01.CCM.0000297886.32564.CF","volume":"36","author":"T Lisboa","year":"2008","unstructured":"Lisboa T, Seligman R, Diaz E, Rodriguez A, Teixeira PJZ, Rello J. C-reactive protein correlates with bacterial load and appropriate antibiotic therapy in suspected ventilator-associated pneumonia. Crit Care Med. 2008;36:166.","journal-title":"Crit Care Med"},{"key":"11381_CR16","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1086\/430382","volume":"40","author":"P P\u00f3voa","year":"2005","unstructured":"P\u00f3voa P, Coelho L, Almeida E, Fernandes A, Mealha R, Moreira P, et al. Pilot study evaluating C-Reactive protein levels in the assessment of response to treatment of severe bloodstream infection. Clin Infect Dis. 2005;40:1855\u20137.","journal-title":"Clin Infect Dis"},{"key":"11381_CR17","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s13054-020-02946-y","volume":"24","author":"I Borges","year":"2020","unstructured":"Borges I, Carneiro R, Bergo R, Martins L, Colosimo E, Oliveira C, et al. Duration of antibiotic therapy in critically ill patients: a randomized controlled trial of a clinical and C-reactive protein-based protocol versus an evidence-based best practice strategy without biomarkers. Crit Care. 2020;24:281.","journal-title":"Crit Care"},{"key":"11381_CR18","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1001\/jama.2020.6348","volume":"323","author":"E von Dach","year":"2020","unstructured":"von Dach E, Albrich WC, Brunel A-S, Prendki V, Cuvelier C, Flury D, et al. Effect of C-Reactive Protein\u2013Guided antibiotic treatment duration, 7-Day treatment, or 14-Day treatment on 30-Day clinical failure rate in patients with uncomplicated Gram-Negative bacteremia: A randomized clinical trial. JAMA. 2020;323:2160\u20139.","journal-title":"JAMA"},{"key":"11381_CR19","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1097\/CCM.0b013e31828e969f","volume":"41","author":"CF Oliveira","year":"2013","unstructured":"Oliveira CF, Botoni FA, Oliveira CRA, Silva CB, Pereira HA, Serufo JC, et al. Procalcitonin versus C-Reactive protein for guiding antibiotic therapy in sepsis: A randomized trial**. Crit Care Med. 2013;41:2336.","journal-title":"Crit Care Med"},{"key":"11381_CR20","doi-asserted-by":"publisher","first-page":"R169","DOI":"10.1186\/cc10313","volume":"15","author":"P P\u00f3voa","year":"2011","unstructured":"P\u00f3voa P, Teixeira-Pinto AM, Carneiro AH. C-reactive protein, an early marker of community-acquired sepsis resolution: a multi-center prospective observational study. Crit Care. 2011;15:R169.","journal-title":"Crit Care"},{"key":"11381_CR21","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ijid.2020.03.063","volume":"95","author":"P P\u00f3voa","year":"2020","unstructured":"P\u00f3voa P, Garvik OS, Vinholt PJ, Pedersen C, Jensen TG, Kolmos HJ, et al. C-reactive protein and albumin kinetics after antibiotic therapy in community-acquired bloodstream infection. Int J Infect Dis. 2020;95:50\u20138.","journal-title":"Int J Infect Dis"},{"key":"11381_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2024.08.017","author":"B Spellberg","year":"2024","unstructured":"Spellberg B, Nielsen TB, Phillips MC, Ghanem B, Boyles T, Jegorovi\u0107 B, et al. Revisiting diagnostics: erythrocyte sedimentation rate and C-reactive protein: it is time to stop the zombie tests. Clin Microbiol Infect. 2024. https:\/\/doi.org\/10.1016\/j.cmi.2024.08.017.","journal-title":"Clin Microbiol Infect"},{"key":"11381_CR23","doi-asserted-by":"publisher","first-page":"106161","DOI":"10.1016\/j.jinf.2024.106161","volume":"88","author":"J Wei","year":"2024","unstructured":"Wei J, Uppal A, Nganjimi C, Warr H, Ibrahim Y, Gu Q, et al. No evidence of difference in mortality with amoxicillin versus co-amoxiclav for hospital treatment of community-acquired pneumonia. J Infect. 2024;88:106161.","journal-title":"J Infect"},{"key":"11381_CR24","doi-asserted-by":"publisher","first-page":"e713","DOI":"10.1093\/infdis\/jiae639","volume":"231","author":"J Wei","year":"2025","unstructured":"Wei J, Walker AS, Eyre DW. Addition of macrolide antibiotics for hospital treatment of Community-Acquired pneumonia. J Infect Dis. 2025;231:e713\u201322.","journal-title":"J Infect Dis"},{"key":"11381_CR25","doi-asserted-by":"crossref","unstructured":"Wei J, Yuan K, Luk A, Walker AS, Eyre DW. Community-acquired pneumonia identification from electronic health records in the absence of a gold standard: A Bayesian latent class analysis. PLOS Digital Health. 2025;4(7):e0000936.","DOI":"10.1371\/journal.pdig.0000936"},{"key":"11381_CR26","doi-asserted-by":"publisher","first-page":"e4507","DOI":"10.1093\/cid\/ciaa932","volume":"73","author":"RW Moehring","year":"2021","unstructured":"Moehring RW, Ashley ESD, Davis AE, Dyer AP, Parish A, Ren X, et al. Development of an electronic definition for De-escalation of antibiotics in hospitalized patients. Clin Infect Dis. 2021;73:e4507\u201314.","journal-title":"Clin Infect Dis"},{"key":"11381_CR27","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jclinepi.2020.09.020","volume":"130","author":"E Pritchard","year":"2021","unstructured":"Pritchard E, Fawcett N, Quan TP, Crook D, Peto TEA, Walker AS. Combining Charlson and elixhauser scores with varying lookback predicated mortality better than using individual scores. J Clin Epidemiol. 2021;130:32\u201341.","journal-title":"J Clin Epidemiol"},{"key":"11381_CR28","doi-asserted-by":"crossref","unstructured":"Yuan K, Yoon CH, Gu Q, Munby H, Walker AS, Zhu T, et al. Transformers and large language models are efficient feature extractors for electronic health record studies. Commun Med. 2025;5(1):1\u20139.","DOI":"10.1038\/s43856-025-00790-1"},{"key":"11381_CR29","unstructured":"Royal College of Physicians. National Early Warning Score (NEWS) 2: Standardising the assessment ofacute-illness severity in the NHS. Updated report of a working party. London: RCP, 2017."},{"key":"11381_CR30","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1093\/qjmed\/hcn099","volume":"101","author":"R Thi\u00e9baut","year":"2008","unstructured":"Thi\u00e9baut R, Walker S. When it is better to estimate a slope with only one point. QJM: Int J Med. 2008;101:821\u20134.","journal-title":"QJM: Int J Med"},{"key":"11381_CR31","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S1369-5274(00)00242-3","volume":"4","author":"K Poole","year":"2001","unstructured":"Poole K. Multidrug resistance in Gram-negative bacteria. Curr Opin Microbiol. 2001;4:500\u20138.","journal-title":"Curr Opin Microbiol"},{"key":"11381_CR32","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1017\/ice.2017.94","volume":"38","author":"JS Gerber","year":"2017","unstructured":"Gerber JS, Hersh AL, Kronman MP, Newland JG, Ross RK, Metjian TA. Development and application of an antibiotic spectrum index for benchmarking antibiotic selection patterns across hospitals. Infect Control Hosp Epidemiol. 2017;38:993\u20137.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"11381_CR33","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00134-002-1209-6","volume":"28","author":"P P\u00f3voa","year":"2002","unstructured":"P\u00f3voa P. C-reactive protein: a valuable marker of sepsis. Intensive Care Med. 2002;28:235\u201343.","journal-title":"Intensive Care Med"},{"key":"11381_CR34","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1172\/JCI200318921","volume":"111","author":"MB Pepys","year":"2003","unstructured":"Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111:1805\u201312.","journal-title":"J Clin Invest"},{"key":"11381_CR35","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/2110-5820-2-32","volume":"2","author":"P P\u00f3voa","year":"2012","unstructured":"P\u00f3voa P, Salluh JIF. Biomarker-guided antibiotic therapy in adult critically ill patients: a critical review. Ann Intensiv Care. 2012;2:32.","journal-title":"Ann Intensiv Care"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11381-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11381-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11381-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T18:58:32Z","timestamp":1757357912000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11381-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11381"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11381-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5327221\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"27 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the National Research Ethics Service South Central Oxford C Research Ethics Committee (19\/SC\/0403) and the National Confidentiality Advisory Group (19\/CAG\/0144). The requirement for informed consent from the study subjects was waived by the National Research Ethics Service South Central Oxford C Research Ethics Committee (19\/SC\/0403) and the National Confidentiality Advisory Group (19\/CAG\/0144), UK, under Sect.\u00a0251 of the NHS Act 2006. Patients who choose to opt out of their data being used in research are not included in the study. The study was carried out in accordance with all relevant guidelines and regulations, and the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"\u00a0Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"987"}}